• Joshua M Diamond, Edward Cantu, Carolyn S Calfee, Michaela R Anderson, Emily S Clausen, ShashatyMichael G SMGSDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine., Andrew M Courtwright, Laurel Kalman, Michelle Oyster, Maria M Crespo, Christian A Bermudez, Luke Benvenuto, Scott M Palmer, Laurie D Snyder, Matthew G Hartwig, Jamie L Todd, Keith Wille, Chadi Hage, John F McDyer, Christian A Merlo, Pali D Shah, Jonathan B Orens, Gundeep S Dhillon, Ann B Weinacker, Vibha N Lama, Mrunal G Patel, Jonathan P Singer, Jesse Hsu, A Russell Localio, and Jason D Christie.
• Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine.
• Am. J. Respir. Crit. Care Med. 2024 Jan 1; 209 (1): 9110091-100.

AbstractRationale: Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Prior studies implicated proxy-defined donor smoking as a risk factor for PGD and mortality. Objectives: We aimed to more accurately assess the impact of donor smoke exposure on PGD and mortality using quantitative smoke exposure biomarkers. Methods: We performed a multicenter prospective cohort study of lung transplant recipients enrolled in the Lung Transplant Outcomes Group cohort between 2012 and 2018. PGD was defined as grade 3 at 48 or 72 hours after lung reperfusion. Donor smoking was defined using accepted thresholds of urinary biomarkers of nicotine exposure (cotinine) and tobacco-specific nitrosamine (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol [NNAL]) in addition to clinical history. The donor smoking-PGD association was assessed using logistic regression, and survival analysis was performed using inverse probability of exposure weighting according to smoking category. Measurements and Main Results: Active donor smoking prevalence varied by definition, with 34-43% based on urinary cotinine, 28% by urinary NNAL, and 37% by clinical documentation. The standardized risk of PGD associated with active donor smoking was higher across all definitions, with an absolute risk increase of 11.5% (95% confidence interval [CI], 3.8% to 19.2%) by urinary cotinine, 5.7% (95% CI, -3.4% to 14.9%) by urinary NNAL, and 6.5% (95% CI, -2.8% to 15.8%) defined clinically. Donor smoking was not associated with differential post-lung transplant survival using any definition. Conclusions: Donor smoking associates with a modest increase in PGD risk but not with increased recipient mortality. Use of lungs from smokers is likely safe and may increase lung donor availability. Clinical trial registered with www.clinicaltrials.gov (NCT00552357).

13 keywords...

hide…